Company Overview of AbGenomics International, Inc.
AbGenomics International, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. It offers AbGn-168, an immunomodulating investigational therapeutic antibody against CD162 that induces apoptosis of late-stage activated T cells and other immune cells, as well as spare naive, regulatory, and memory T cells; various animal disease models, such as CIA, NOD, and allergy, as well as transplantation rejection/GVHD in murine and DTH in non-human primate; and autoimmune diseases, including rheumatoid arthritis, Crohn's disease, lupus, and psoriasis. The company also provides antibody-7 ...
4984 El Camino Real
Los Altos, CA 94022
Founded in 2000
Key Executives for AbGenomics International, Inc.
Founder, Chairman of the Board and Chief Executive Officer
Director of Operation, Corporate Secretary and Director
Director of IP Management & Quality Assurance
Director of Project & Alliance Managements
Compensation as of Fiscal Year 2015.
AbGenomics International, Inc. Key Developments
AbGenomics International, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:00 AM
Sep 3 15
AbGenomics International, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:00 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.
AbGenomics International Announces Initiation of Phase-Ib/IIa Clinical Trial of Neihulizumab (AbGn-168H) for the Treatment of Steroid Refractory Acute GvHD (aGvHD)
May 18 15
AbGenomics International announced the start of a phase-Ib/IIa clinical trial using the lead compound Neihulizumab (AbGn-168H) to treat steroid refractory acute GvHD (aGvHD). This investigator-initiated trial is sponsored by Stanford University in its bone marrow transplant program. The primary objective of the study is to evaluate the safety and efficacy of AbGn-168H in patients with steroid refractory aGvHD in the post-allogeneic transplantation setting. aGVHD is a major complication of hematopoietic cell transplantation (HCT) that accounts for most non-relapse mortality and limits the use of HCT. Steroid refractory aGVHD carries an especially high mortality of between 60-85%. According to key opinion leaders in this field, a huge unmet medical need of aGvHD needs to be satisfied under the existing therapies. Prior to the aGvHD trial, the proof of clinical efficacy and safety of AbGn-168H, a humanized monoclonal antibody, has been well demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Most recently, AbGenomics has also initiated an open-label, multi-center phase II study for psoriatic arthritis. The company is dedicated to bring forth this potential game-changing therapeutic candidate for the treatment of various inflammatory diseases.
AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM
Sep 9 14
AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|